LBA35 Camrelizumab (C) plus rivoceranib (R) vs. sorafenib (S) as first-line therapy for unresectable hepatocellular carcinoma (uHCC): A randomized, phase III trial
S. Qin, L.S. Chan, Shanzhi Gu, Y. Bai, Z. Ren, Xinyan Lin, Z. Chen, Wensen Jia, Yumeng Jin, Yuxing Guo, A.V. Sultanbaev, M. Pazgan-Simon, Margaryta Pisetska, X. Liang, Chi Chen, Zehua Nie, L. Wang, Ann‐Lii Cheng, A. Kaseb, A. Vogel
Topics & Concepts
MedicineSorafenibHepatocellular carcinomaInternal medicineOncologyRandomized controlled trialHepatocellular Carcinoma Treatment and PrognosisLiver physiology and pathologyCancer Immunotherapy and Biomarkers